NCT00939614已完成1 期
A Randomized, Open Label, Single Dose, Crossover, Bioequivalence Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited., India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
- 主要终点
- Bioequivalence
研究概览
简要总结
-
Objective:
-
A randomized, open label, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Lamotrigine 2 x 25mg IR tablets of Torrent Pharmaceuticals Limited, India and Lamictal ® (Lamotrigine) 2 x 25 mg tablets of Glaxo-SmithKline, USA, in healthy human adult subjects, under fasting conditions.
-
Study Design:
-
Randomized, open label, two treatment, two period, two sequence, single dose, crossover, in 24+2 healthy human adult subjects to compare the single dose bioavailability of Torrent's Lamotrigine Tablets 2 × 25 mg and Lamictal® Tablets 2 × 25 mg of GlaxoSmithKline. Dosing periods were separated by a washout period of at least 21 days.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Healthy adult subjects of either sex between 18-55 years of age (inclusive), having a body mass index (BMI) between 18 and 27 kg/m
- •Subjects who have no evidence of underlying disease during screening and whose physical examination is performed within 21 days prior to commencement of the study.
- •Subjects whose screening laboratory values are within normal limits or values outside normal limits considered by the physician/Principal Investigator to be of no clinical significance.
- •Informed consent given in written form according to section 11.3 of the protocol.
- •Female Subjects:
- •of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.
- •postmenopausal for at least 1 year.
- •surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject).
排除标准
- •Cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.
- •Alcohol dependence, alcohol abuse or drug abuse within past one year.
- •Moderate to heavy smoking (> 10 cigarettes/day) or consumption of tobacco products.
- •History of difficulty in swallowing tablet.
- •Clinically significant illness within 4 weeks before the start of the study
- •Asthma, urticaria or other allergic type reactions after taking any medication.
- •Positive urine drug screening, HIV, Hepatitis B & C tests.
- •Any history of hypersensitivity to Lamotrigine.
- •Existence of any surgical or medical condition, which, in the judgment of clinical investigator might interfere with the pharmacokinetics of the drug or likely to compromise the safety of the subject.
- •Inability to communicate or co-operate with the investigator due to language problem, attitude, poor mental development/impaired cerebral function.
结局指标
主要结局
Bioequivalence
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fed ConditionsHealthyNCT00759915Actavis Inc.36
已完成
1 期
Comparison of Two KADIAN 10 mg Capsules to a KADIAN 20 mg Capsule Under Fasted ConditionsHealthyNCT00759902Actavis Inc.36
已完成
1 期
Bioequivalence Study of Bafiertam 190 mg and Vumerity® 462 mg Delayed-Release Capsules in Fasting Healthy SubjectsRelapsing Remitting Multiple SclerosisNCT05181215Banner Life Sciences LLC46
已完成
1 期
Bioequivalence Study of Klaribact (Clarithromycin) 500 mg, Film Coated TabletBioequivalence StudyHealthy VolunteersNCT05436769University of Karachi24
已完成
1 期
To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy VolunteersHealthyNCT02690727Rhizen Pharmaceuticals SA18